Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Addex TherapeuticsFRA:APE EV-to-OCF is -2.24 as of Aug. 13, 2026. The stock has 6 warning signs investors should review. Among 1,408 Biotechnology companies, Addex Therapeutics ranks worse than 56.53% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Addex Therapeutics's Enterprise Value is €5.66 Mil.
Addex Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was €-2.52 Mil. Therefore, Addex Therapeutics's EV-to-OCF for today is -2.24.
The historical rank and industry rank for Addex Therapeutics's EV-to-OCF or its related term are showing as below:
FRA:APE'
s EV-to-OCF Range Over the Past 10 Years
Min: -18.56 Med: -0.9 Max: 0.42
Current: -2.27
During the past 13 years, the highest EV-to-OCF of Addex Therapeutics was 0.42. The lowest was -18.56. And the median was -0.90.
FRA:APE's EV-to-OCF is ranked worse than 56.53% of 1408
companies
in the Biotechnology industry
Industry Median: -3.53
vs FRA:APE: -2.27
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Addex Therapeutics's PE Ratio (TTM) for today is calculated as:
Addex Therapeutics's share price for today is €0.0395.
Addex Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.054.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Addex Therapeutics EV-to-OCF Related Terms
Addex Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Addex Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Addex Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Addex Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Addex Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Addex Therapeutics's EV-to-OCF falls into.
Addex Therapeutics's current Enterprise Value is €5.66 Mil.
Addex Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Addex Therapeutics (FRA:APE) has a EV-to-OCF of -2.24 as of Aug. 13, 2026. According to the industry distribution chart, Addex Therapeutics ranks #796 out of 1408 companies in the Biotechnology industry, placing it in the top 56.5%.
Is Addex Therapeutics' EV-to-OCF too high?
Addex Therapeutics' current EV-to-OCF is -2.24. Based on the distribution chart, Addex Therapeutics ranks #796 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint.
How does Addex Therapeutics' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Addex Therapeutics ranks #796 out of 1408 companies for EV-to-OCF. This places Addex Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Addex Therapeutics's current EV-to-OCF is -2.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Addex Therapeutics (FRA:APE) has a current EV-to-OCF of -2.24. The current EV-to-OCF is -2.24. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE), the current EV-to-OCF is -2.24 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:APE has been successfully added to your 
